Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 7Fluorouracil 3Drug Therapy 3spartalizumab 2derazantinib 2Leucovorin 2trametinib 1tislelizumab 1silmitasertib 1seribantumab 1pertuzumab 1olutasidenib 1galactomannan 1exatecan 1durvalumab 1becatecarin 1Tegafur 1Standard of Care 1S 1 (combination) 1Ritonavir 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Microscopy, Confocal 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bile Duct Neoplasms × galactomannan × Clear all
NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Galectin Therapeutics Inc.

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡